Todos Med Stock Price, News & Analysis

Todos Medical, Ltd. (OTCQB: TOMDF) has secured a new agreement with convertible noteholders, instituting a 90-day moratorium on conversion and a sales restriction on common shares. This measure follows the expiration of a prior agreement on December 10, 2021, indicating increased investor confidence. The company anticipates a surge in demand for COVID-19 testing and its 3CL protease inhibitor products, which have recently gained FDA claims. Additionally, their European licensing partnership is expected to boost fourth-quarter revenue significantly, supporting efforts for national stock exchange listing.

Todos Medical, Ltd. (OTCQB: TOMDF) will be featured on Benzinga’s All Access Conference on December 14, 2021, at 10:20 AM EST. CEO Gerald Commissiong will discuss the company’s strategies for Tollovir approval and advancements in the testing business. Attendees will gain insights into Todos’ future plans. The event will be available online, with an archive provided for those unable to attend live. Todos Medical, founded in Israel, focuses on life-saving diagnostic solutions, including its proprietary cancer-screening technologies.

Todos Medical, Ltd. (OTCQB: TOMDF) has announced the acquisition of two new reference lab testing contracts through its CLIA/CAP lab, Provista Diagnostics, responding to increased COVID-19 testing demand from laboratories in Georgia and New Jersey. The lab is currently processing an average of 1,000 PCR samples daily, with potential to scale up to 5,000. CEO Gerald Commissiong emphasized the ongoing relevance of COVID-19 testing amid rising Omicron variant cases, predicting a shift to testing mandates as vaccination does not eliminate transmission risks.

Todos Medical, Ltd. (OTCQB: TOMDF) will present at the Emerging Growth Conference on December 8, 2021, at 3:00pm EST. The online event allows shareholders to interact with CEO Gerald Commissiong. Registration is available for attendees, and an archived webcast will be accessible afterward. Todos Medical, founded in Israel, specializes in medical diagnostics, including cancer detection and COVID-19 solutions. The company aims to commercialize innovative diagnostic tests, reinforcing its commitment to advance healthcare technology.

Todos Medical (OTCQB: TOMDF) announced that all 31 patients in the Tollovir® Phase 2 clinical trial for hospitalized COVID-19 patients have completed their participation. Data entry for statistical analysis is underway, led by Dr. Jules Mitchel, with completion expected in December 2021. The management team will host a business update call on December 2, 2021, at 4:30 PM EST to discuss progress and future outlook.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a conference call on December 2, 2021, at 4:30 p.m. EST, to discuss the company's progress and future strategy. The call will feature CEO Gerald E. Commissiong and is accessible via a direct dial-in number. Todos Medical focuses on innovative diagnostics for cancer detection and has acquired Provista Diagnostics for its testing capabilities. The company is also developing COVID-19 therapeutics and tests for neurodegenerative disorders like Alzheimer’s. More details about the call can be found on their website.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its lab, Provista Diagnostics, can detect the Omicron variant of SARS-CoV-2 using its PCR test kits. The lab has reached a testing capacity of 20,000 tests daily and plans to expand equipment to handle potential surges. Todos is also introducing Osang’s GeneFinder™ COVID-19 Variants-I RealAMP Kit to enhance variant testing capabilities, allowing for rapid results in under three hours. The company aims to leverage this testing capacity to meet increasing demand amidst the evolving COVID-19 landscape.

Todos Medical, Ltd. (OTCQB: TOMDF) has announced the acquisition of 3CL protease-related assets from NLC Pharma, establishing a majority-owned subsidiary called 3CL Sciences. This unit will focus on developing antiviral therapeutics targeting COVID-19. Dr. Dorit Arad, known for her pioneering research in 3CL protease inhibitors, will serve as Chief Scientific Officer. Initial funding of $2.2 million is committed for 3CL Sciences, which aims to explore new chemical entities and enhance their Tollovir therapeutic candidate currently in Phase 2 trials. The transaction is expected to close on December 15, 2021.

Todos Medical, Ltd. (OTC-PINK:TOMDF) has secured an exclusive licensing and distribution agreement with T-Cell Protect Hellas S.A. for its Tollovid® and Tollovid Daily™ products across Europe. The agreement ensures a minimum of 500,000 bottles sold over 18 months, with an initial order of 50,000 bottles for Greece. Concurrently, T-Cell Protect is investing €1 million in Todos to aid the development of Tollovir, its antiviral candidate targeting coronaviruses, and seeks emergency use authorization for the product. Revenue generation from this agreement is expected to commence in the current quarter.